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Schanzer: Nothing to disclose.Table. Odds ratios for bivariate comparisons of 30-day
outcomes, stratiﬁed by procedure
30-day death,
stroke, MI
Preop ipsilateral
symptom type
Multivariate (adjusted)
logistic model
OR (95% CI) P value
CAS (n ¼ 3236) CVA (v TIA) 1.33 (0.88-2.02) .1812
CVA (v TMB) 2.86 (1.36, 6.01) .0056a
CVA (v ASX) 2.47 (1.70, 3.58) <.0001a
TIA (v TMB) 2.15 (1.04, 4.46) .0393
TIA (v ASX) 1.86 (1.32, 2.62) .0004a
TMB (v ASX) 0.86 (0.43, 1.75) .6857
CEA (n ¼ 5780) CVA (v TIA) 1.30 (0.83, 2.03) .2492
CVA (v TMB) 2.56 (1.18, 5.57) .0174
CVA (v ASX) 2.10 (1.45, 3.05) <.0001a
TIA (v TMB) 1.97 (0.91, 4.26) .0837
TIA (v ASX) 1.62 (1.13, 2.31) .0084
TMB (v ASX) 0.82 (0.40, 1.70) .5917
aDenotes signiﬁcant P-values of <.0083, accounting for multiple
comparisons.PVSS4.
Revascularization of Asymptomatic Carotid Stenosis Is
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Objectives: Outcomes of carotid endarterectomy
(CEA) or angioplasty and stenting (CAS) for asymptomatic
disease in patients on dialysis are not well characterized,
with questionable stroke prevention and survival. This
study reports outcomes of carotid revascularization in
asymptomatic US dialysis patients.
Methods: Using US Renal Data System (USRDS)
databases, we identiﬁed all dialysis patients who underwent
CEA and CAS for asymptomatic disease from 2005-2008.
CEA and CAS were identiﬁed by CPT codes, and symptom
status and comorbidities by ICD9 codes. Primary
outcomes were stroke, cardiac complications and death at
30 days, and at 1 and 3 years. Predictors of mortality
were identiﬁed using regression models.
Results: Out of 738,561 dialysis patients, 2131
asymptomatic patients had carotid revascularization
(1805 CEA, 326 CAS). The mortality rate was 4.7% at
30 days (4.6% CEA, 4.9% CAS; P ¼ .81), and 24.6% at
1yr (23.8% CEA, 29.7% CAS; P ¼ .054). Kaplan Meier
estimates of survival were 75.1% at 1yr (75.9% CEA,
70.7% CAS; P ¼ .17), and 43.1% at 3 yrs (43.4% CEA,
41.7% CAS; P ¼ .58). Stroke rate was 6.5% at 30 days
(6.4% CEA, 6.8% CAS; P ¼ .81) and 13.6% at 1yr
(13.3% CEA, 15.3% CAS; P ¼ .43). Cardiac complications
occurred in 22.0% of patients (3.2% MI) at 30 days (22.2%
CEA, 20.7% CAS; P ¼ .69). The combined stroke or death
rate was 10.2% at 30 days (10.0% for CEA, and 11.1% for
CAS; P ¼ .56), and 33.5% at 1 year (32.2% CEA, 40.6%
CAS; P ¼ .013). Age > 70, time on dialysis, and history
of transplant were predictive of mortality. Compared to
the general population, patients who underwent CEA or
CAS had increased mortality (P < .001).
Conclusions: Patients on dialysis have high peri-oper-
ative and long term stroke or death rates following CEA or
CAS for asymptomatic stenosis. Carotid intervention in
these patients appears to be inappropriate.
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Nothing to disclose; T. H. Yuo: Nothing to disclose.Table. Comorbidities and risk factors by type of procedure
CEA, No. (%)
Age (in years, mean 6 SD) Sex
(Male) Diabetes History of
transplant Ischemic heart
disease PVD Hypertension
Smokers Presence of neoplasm
Time on dialysis (in years,
mean 6 SD) BMI (mean 6 SD)
69.1 (9.46) 1116 (60.3%) 997 (55.5%)
261 (14.1%) 399 (39.8%) 447 (24.9%)
1545 (85.9%) 149 (8.3%) 92 (5.1%)
3.5 (3.95) 27.8 (6.42)PVSS5.
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Objectives: To determine the effect of speciﬁc
symptom types on outcomes of CEA and CAS in contem-
porary vascular surgical practice.
Methods: Retrospective review of all SVS-VR patients
treated with CEA or CAS. Patients were segregated by 12-
month preprocedural ipsilateral symptom status: stroke
(CVA), hemispheric transient ischemic attack (TIA), tran-
sient monocular blindness (TMB), or asymptomatic
(ASX). Simple and risk-adjusted odds ratios were used to
compare the likelihood of the 30-day outcomes of death,
CVA, myocardial infarction (MI), and the composite
outcomes of death/CVA, and death/CVA/MI.
Results: Symptom type signiﬁcantly inﬂuences risk-
adjusted 30-day outcomes for carotid intervention, more
markedly in patients undergoing CAS than CEA (Table).
Bivariate analyses conﬁrm a hierarchical relationship, withCAS, No. (%) P value
69.1 (8.98) 213 (64.0%) 189 (57.6%)
38 (11.4%) 61 (35.5%) 94 (28.7%)
276 (84.2%) 18 (5.5%) 22 (6.7%)
3.2 (3.60) 28.0 (6.64)
.99 .21 .47 .19 .28 .15 .40
.08 .24 .30 .71
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6S Abstracts May Supplement 2013preprocedural stroke predicting the poorest outcomes, fol-
lowed by TIA. 30-day outcomes for the TMB and ASX
patient groups were equivalent in both treatment arms.
Conclusions: Presenting symptom type signiﬁcantly
affects the 30-day outcomes of carotid intervention in
contemporary vascular surgical practice, with a more prom-
inent effect on CAS outcomes than CEA outcomes.
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Objectives: Advances in medical therapy and endovas-
cular techniques have caused uncertainty regarding the role
of carotid revascularization. We hypothesized that these
advances affect regional utilization of carotid endarterec-
tomy (CEA) and carotid artery stenting (CAS).
Methods: We used Medicare claims (2002-2010) to
calculate annual rates of CAS and CEA, and examined
changes by procedure type. To assess regional preferences
surrounding CAS we calculated, within hospital referral
regions, the proportion of revascularizations comprised
by CAS, and examined determinants of high CAS
utilization.Fig.Results: The annual number of carotid revasculariza-
tions decreased by 30% over 8 years (3.2 to 2.3 per
1000; P ¼ .005). While rates of CEA declined 37% (3.0
to 1.9 per 1000; P ¼ .005), CAS utilization changed little
(0.39 to 0.32 per 1000; P ¼ NS; Fig). The proportion of
carotid revascularizations that were CAS varied across the
US, from 0.4% (Marquette, MI) to 44% (St. Joseph, MI)
of all carotid revascularizations. In multivariable models
accounting for age, sex and race, regions with the highest
density of cardiologists had the highest utilization of CAS
(OR 2.7; 95% CI 1.4-5.1; P ¼ .002).
Conclusions: Even though CEA has decreased by
37% over 8 years, utilization of CAS has remained constant.
Patients living in regions with the highest density of cardi-
ologists are most likely to receive CAS. Future efforts to
deﬁne the role carotid revascularization will require a multi-
disciplinary approach to ensure uniform health policy
implementation.
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